AVT 80
Alternative Names: AVT-80Latest Information Update: 18 Mar 2025
At a glance
- Originator Alvotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 13 Dec 2024 AVT 80 is available for licensing as of 13 Dec 2024. https://www.alvotech.com/pipeline/partnerships
- 13 Dec 2024 Preclinical trials in Unspecified in Iceland (SC)
- 13 Dec 2024 Alvotech Swiss plans pharmacokinetics phase I trial (In volunteers) in New Zealand (SC) in February 2025 (NCT06732804)